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Interferon-␥ (IFN␥) treatment of adipocytes results in
a down-regulation of the peroxisome proliferator-activated receptor ␥ (PPAR␥). The decrease in PPAR␥ expression is mediated by inhibition of PPAR␥ synthesis
and increased degradation of PPAR␥. In this study, we
demonstrate that both PPAR␥1 and PPAR␥2 are targeted to the proteasome under basal conditions and that
PPAR␥1 is more labile than PPAR␥2. The IFN␥-induced
increase in PPAR␥ turnover is blocked by proteasome
inhibition and is accompanied by an increase in PPAR␥polyubiquitin conjugates. In addition, IFN␥ treatment
results in the transcriptional activation of PPAR␥. Similar to ligand-dependent activation of PPAR␥, IFN␥-induced activation was greater in the phosphorylationdeficient S112A form of PPAR␥ when compared with
wild-type PPAR␥. Moreover, the inhibition of ERKs 1
and 2 with a MEK inhibitor, U1026, lead to an inhibition
in the decay of PPAR␥ proteins, indicating that serine
phosphorylation influences the degradation of PPAR␥
in fat cells. Our results also demonstrate that the proteasome-dependent degradation of PPAR␥ does not require nuclear export. Taken together, these results indicate that PPAR␥ is targeted to the ubiquitinproteasome pathway for degradation under basal
conditions and that IFN␥ leads to an increased targeting
of PPAR␥ to the ubiquitin-proteasome system in a process that is affected by ERK-regulated serine phosphorylation of PPAR␥ proteins.
PPAR␥1 is a member of the nuclear hormone receptor family,
a group of transcription factors that are activated by small
lipophilic ligands (1). PPAR␥ exists as two isoforms, PPAR␥1
and PPAR␥2, which are produced by a combination of different
promoters and alternative splicing (2). There is also a PPAR␥3
gene that codes for a protein that is identical to PPAR␥1 (3).
PPAR␥1 is predominantly expressed in fat cells but occurs in
low levels in multiple tissues. PPAR␥2 has an N-terminal extension of 30 amino acids and is very highly expressed in
adipocytes (4, 5). Deletion of the PPAR␥ gene in mice results in
placental dysfunction and embryonic lethality (6, 7).
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PPAR␥ has been implicated in the regulation of systemic
insulin sensitivity. This was first demonstrated when PPAR␥
was shown to be a functional receptor for the synthetic antidiabetic thiazolidinediones (TZDs) (8). Thiazolidinediones are
specific high affinity ligands for PPAR␥ and the order of their
receptor binding affinities in vitro mirrors their antihyperglycemic activity in vivo (9). Direct evidence for the association
between PPAR␥ and insulin sensitivity comes from genetic
studies showing that mutations in the ligand-binding domain
of PPAR␥ are associated with severe insulin resistance. Although not obese, these patients developed type 2 diabetes as
well as early onset hypertension (10). Also, insulin has been
shown to acutely regulate the expression of PPAR␥ in human
adipocytes (11), and mice that only express one copy of the
PPAR␥ gene have been shown to be more sensitive to insulin
(12). We have recently demonstrated that IFN␥ results in a
substantial loss of PPAR␥ expression by regulating two cellular
events: 1) targeting PPAR␥ to the proteasome for degradation,
and 2) inhibiting the synthesis of PPAR␥ (13). Moreover, prolonged IFN␥ treatment of 3T3-L1 adipocytes also results in
the development of insulin resistance (13) and supports the
hypothesis that PPAR␥ is involved in conferring insulin
sensitivity.
Interferon-␥ (IFN␥) is a cytokine that is primarily known for
its roles in immunological responses but has also been shown to
affect fat metabolism and adipocyte gene expression. In adipocytes, IFN␥ treatment results in a decrease of lipoprotein lipase
(LPL) activity and increased lipolysis (14). In 3T3-F442 adipocytes, exposure to IFN␥ results in a decreased expression of
lipoprotein lipase and fatty acid synthase. Also, in various
rodent preadipocyte cell lines, IFN␥ inhibits the differentiation
of preadipocytes (15–17). Acute IFN␥ treatment of cultured and
native rat adipocytes results in a dose- and time-dependent
activation of STATs 1 and 3 (18). Moreover, there are studies
(19 –21) linking IFN␥ and insulin resistance in humans. IFN␥
has been implicated in the development of insulin resistance
during viral infections (20), and IFN␥ therapy of cancer patients has been associated with the development of hyperglycemia (21).
The ubiquitin-proteasome pathway is essential for the degradation of short lived proteins, the levels of which are regulated constitutively or in response to changes in the cellular
environment (22, 23). Transcription factors and tumor suppressors are among the proteins regulated by the ubiquitin-proteasome pathway, and included in this group are members of the
nuclear hormone receptor superfamily (24, 25). Ligand-dependent down-regulation by the ubiquitin-proteasome system has
been demonstrated for several members of the nuclear hormone receptor family, including the estrogen (26, 27), progesterone (28), thyroid hormone (29), and aryl hydrocarbon receptors (30).
Substrates of the ubiquitin-proteasome system are targeted
to the proteasome after covalent attachment of multiple ubiquitin molecules. Ubiquitin, a 76 amino acid protein, is initially
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activated by E1, the ubiquitin-activating enzyme. Activated
ubiquitin is then transferred to a ubiquitin-conjugating enzyme
(E2), which generally shuttles ubiquitin to ubiquitin ligase
(E3). E3 is bound to the targeted substrate and catalyzes the
covalent attachment of ubiquitin to the substrate. Once the
first ubiquitin is transferred to the substrate, a polyubiquitination chain is generated via a series of isopeptide linkages.
The multiubiquitinated substrate protein is then degraded by
the 26 S proteasome in an ATP-dependent manner (31).
Our recent studies (13) have shown that acute IFN␥ treatment of 3T3-L1 adipocytes results in a repression of PPAR␥
transcription that is independent of new protein synthesis. Yet,
we also demonstrated that the half-life of PPAR␥ proteins was
shorter following IFN␥ treatment. In the current investigation,
we observed that proteasomal inhibitors attenuate the TZDand IFN␥-induced decrease in PPAR␥ expression. Moreover,
we demonstrate that IFN␥ treatment is associated with an
increase in the formation of polyubiquitin-PPAR␥ conjugates in
3T3-L1 adipocytes. Together, these data indicate that IFN␥
signaling results in the increased targeting of PPAR␥ to the
ubiquitin-proteasome system in adipocytes. In addition, we
have shown that like TZDs, IFN␥ increases the transcriptional
activity of PPAR␥. Also, the IFN␥-induced activation of a phosphorylation-deficient mutant of PPAR␥2 (S112A) is substantially greater than the IFN␥ activation of wild-type PPAR␥2.
Our results suggest that phosphorylation of PPAR␥2 at Ser112
contributes to the targeting of PPAR␥ to the ubiquitin-proteasome pathway. Finally, these studies indicate that the IFN␥mediated ubiquitin-proteasome-dependent degradation of
PPAR␥ occurs in the nucleus.
EXPERIMENTAL PROCEDURES

Materials—Dulbecco’s modified Eagle’s medium (DMEM), OptiMEM, and fetal bovine serum were purchased from Invitrogen. Calf
serum was purchased from Sigma. Murine IFN␥ was purchased from
Roche Molecular Biochemicals. PPAR␥ monoclonal (E-8, no. sc-7273)
and polyclonal (H-100, no. sc-7196) antibodies, Mdm2 monoclonal
(SMP14, no. sc-965) antibody, and a STAT 5A polyclonal (L-20, no.
sc-1081) antibody were purchased from Santa Cruz Biotechnology.
Monoclonal anti-ubiquitin (no. 13–1600) was purchased from Zymed
Laboratories Inc. The proteasome inhibitors epoxomicin, lactacystin,
and MG132 (N-carbobenzoxyl-Leu-Leu-Leucinal) were purchased from
Boston Biochemicals. A luciferase assay system, pSV-␤-galactosidase
control vector, and a ␤-galactosidase enzyme assay kit were purchased
from Promega. FuGENE 6 was purchased from Roche Molecular Biochemicals. Darglitazone was kindly provided by Pfizer.
Constructs—The pSVSport plasmids encoding wild-type PPAR␥ and
the S112A PPAR␥ mutant as well as DR-1 luciferase were the generous
gift of Dr. Bruce Spiegelman (Dana Farber Cancer Institute). The
HA-ubiquitin plasmid and leptomycin B (LMB) were kindly provided
by Dr. Dirk Bohmann (European Molecular Biology Laboratories) and
Dr. Minoru Yoshida (The University of Tokyo), respectively.
Cell Culture—Murine 3T3-L1 preadipocytes were plated and grown
to 2-days postconfluence in DMEM with 10% calf serum. The medium
was changed every 48 h. Cells were induced to differentiate by changing
the medium to DMEM containing 10% fetal bovine serum and 0.5 mM
3-isobutyl-methylxanthine, 1 M dexamethasone, and 1.7 M insulin
(MDI). After 48 h, this medium was replaced with DMEM supplemented with 10% fetal bovine serum, and the cells were maintained in
this medium until used for experimentation. NIH 3T3 cells were grown
in DMEM with 10% calf serum.
Preparation of Whole Cell Extracts—Cell monolayers were rinsed
with phosphate-buffered saline (PBS) and harvested in a lysis buffer
containing 10 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM
EDTA, 1% Triton X-100, 0.5% Nonidet P-40, 1 M phenylmethylsulfonyl
fluoride, 1 M pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10
M leupeptin, and 2 mM sodium vanadate. Samples were extracted on
ice for 30 min prior to centrifugation at 10,000 ⫻ g for 15 min. The
resulting supernatants were analyzed for protein content by BCA analysis (Pierce) according to the manufacturer’s instructions and stored at
⫺80 °C.
Preparation of Nuclear/Cytosolic Extracts—Cell monolayers were
rinsed with PBS and harvested in a nuclear homogenization buffer
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(NHB) containing 20 mM Tris-Cl, pH 7.4, 10 mM NaCl and 3 mM MgCl2.
Nonidet P-40 was added to a final concentration of 0.15%, and the cells
were homogenized with 16 strokes in a Dounce homogenizer. The resulting homogenate was centrifuged at 1500 rpm for 5 min, and the
supernatant was saved as cytosolic extract. The nuclear pellet was
twice resuspended in 0.5 volume of a nuclear homogenization buffer
and centrifuged as before. The nuclear pellet was then resuspended in
an extraction buffer containing 20 mM HEPES pH 7.9, 420 mM NaCl,
0.2 mM EDTA and 25% glycerol. Nuclei were extracted for 30 min on ice
followed by incubation with 200 units of DNase I at room temperature
for 15 min. Finally, the sample was centrifuged at 15,000 rpm for 10
min at 4 °C. The resulting nuclear extract and the previously obtained
cytosolic extract were analyzed for protein content by BCA analysis
(Pierce) according to the manufacturer’s instructions and stored at
⫺80 °C.
Gel Electrophoresis and Immunoblotting—Proteins were separated
in 12% polyacrylamide (National Diagnostics) gels containing SDS according to Laemmli (32) and transferred to nitrocellulose (Bio-Rad) in
25 mM Tris, 192 mM glycine, and 20% methanol. Following transfer, the
membrane was blocked in 4% milk overnight at 4 °C. The immunoblots
were visualized with horseradish peroxidase-conjugated secondary antibodies (Sigma) and enhanced chemiluminescence (Pierce).
Transient Transfection and Luciferase Assay—NIH 3T3 cells were
grown to 60 –70% confluence and transiently transfected with either
wild-type PPAR␥2 or PPAR␥2 S112A. To measure PPAR␥ activity, the
cells were cotransfected with DR-1 luciferase and pSV-␤-galactosidase
to normalize for transfection efficiency. FuGENE 6 was used according
to the manufacturer’s instructions and a FuGENE 6 to DNA ratio of 3:2
was used in the transfections. Transient transfections were carried out
in OptiMEM for 8 h. After 8 h, the media were replaced with DMEM
supplemented with 10% calf serum, and the cells were incubated overnight. Twenty-four hours after transfection, the cells were treated with
IFN␥ (100 units/ml) or darglitazone (TZD) (2.5 M), and the cells were
harvested 6 h later. Cell lysates were prepared and analyzed for luciferase activity and ␤-galactosidase activity according to the manufacturer’s instructions (Promega). PPAR␥ transcriptional activity was reported as the ratio of luciferase activity (relative light units) to
␤-galactosidase activity.
Ubiquitin Conjugation Assay—NIH 3T3 cells were transfected with 2
g of PPAR␥ alone or in combination with 4 g of HA-ubiquitin per 100
mm plate using FuGENE 6 as described above. After 24 h, the cells
were treated with 10 M MG132 for 2 h prior to the addition of IFN␥
(100 units/ml). The cells were harvested after 15- and 30-min incubations and lysed on ice in PBS, pH 7.0, containing 1% Triton X-100, 10
mM N-ethylmaleimide, 1 mM phenylmethylsulfonyl fluoride, 1 M pepstatin and 10 M leupeptin. Immunoprecipitations were performed by
incubation with a polyclonal anti-PPAR␥ followed by incubation with
protein A-Sepharose (RepliGen). PPAR␥-ubiquitin complexes were detected by Western blotting with an anti-HA antibody.
3T3-L1 adipocytes were serum-deprived overnight in OptiMEM, followed by incubation with 10 M MG132 for 2 h. At the end of 2 h, IFN␥
(100 units/ml) was added, and the cells were harvested after 15- and
30-min incubations and lysed on ice in PBS containing 1% Triton X-100,
10 mM N-ethylmaleimide, 1 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, 1 M pepstatin, and 10 M leupeptin. Immunoprecipitations
were performed with a polyclonal anti-PPAR␥, and PPAR␥-ubiquitin
complexes were detected by Western blotting using both anti-PPAR␥
(monoclonal) and anti-ubiquitin antibodies.
PPAR␥ Stability in Vivo—Experiments using 3T3-L1 adipocytes
were carried out in the presence or absence of cycloheximide (5 M) to
examine the effect of IFN␥ on the half-life of PPAR␥ proteins. The
half-lives of PPAR␥1 and PPAR␥2 were calculated based on first order
decay after quantitation of Western blot data using Un-Scan-It software
(Silk Scientific, Inc). IFN␥ was added at 100 units/ml and darglitazone
was added at 2.5 M, where indicated. The adipocytes were incubated
with one of three proteasome inhibitors (5 M lactacystin, 100 nM
epoxomicin, or 10 M MG132) in experiments designed to assay proteasome targeting of PPAR␥. In these experiments, the cells were preincubated with the proteasome inhibitor for 15–30 min prior to adding the
ligand or cycloheximide. A MAPK/ERK kinase (MEK) inhibitor, U0126
(5 M), was used to assay involvement of ERK1/2 in the turnover of
PPAR␥, and the cells were preincubated with U0126 for 30 – 45 min.
Leptomycin B (10 nM) was added as an inhibitor of CRM-1-dependent
nuclear export (33). Cells were pretreated with leptomycin B for 0.5–1
h prior to the addition of ligand or cycloheximide. Vehicle control
additions were performed with either Me2SO (for proteasome inhibitors, TZDs, and U0126) or ethanol (for leptomycin B).
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FIG. 1. PPAR␥ is targeted to the proteasome under basal conditions and after IFN␥ or TZD treatment. Whole cell extracts were
prepared from fully differentiated 3T3-L1 adipocytes that were untreated or treated with 100 units/ml IFN␥ or 2.5 M TZD. Proteasome activity
was inhibited with epoxomicin (100 nM), lactacystin (5 M), or MG132 (10 M). Steady-state levels of PPAR␥ were measured after 6 h. One hundred
micrograms of each extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. The molecular mass
of each protein is indicated to the left of the blot in kDa. The detection system was horseradish peroxidase-conjugated secondary antibodies (Sigma)
and ECL (Pierce). This was a representative experiment independently performed three times.
RESULTS

Basal and IFN␥-mediated Targeting of PPAR␥ to the Proteasome—We have previously shown that treatment of 3T3-L1
adipocytes with IFN␥ leads to a decrease in the half-life of both
PPAR␥ proteins (13). Recent studies by Spiegelman and coworkers (34) have shown that TZDs target PPAR␥ for proteasome-mediated degradation. These results suggest that targeting to the proteasome is an important regulatory event in the
control of PPAR␥ expression. Therefore, we examined PPAR␥
expression in the presence of three distinct proteasome inhibitors. As shown in Fig. 1, treatment of 3T3-L1 adipocytes with
either epoxomicin, lactacystin, or MG132 resulted in an increase in the levels of PPAR␥ proteins under basal conditions
or in the presence of IFN␥ or TZD. Lactacystin and epoxomicin
are highly specific proteasome inhibitors and confirm that the
observed effects on degradation are due to proteasomal targeting (35, 36). As shown in Fig. 1, under steady-state conditions,
IFN␥ treatment of 3T3-L1 adipocytes leads to a substantial loss
of PPAR␥ when compared with control levels. The decrease in
PPAR␥ after IFN␥ treatment is slightly greater than the decrease associated with the presence of synthetic ligand (TZD).
Inhibition of the proteasome substantially reduces the IFN␥induced decrease in PPAR␥ expression. These results indicate
that the loss of PPAR␥ following IFN␥ treatment is mediated
by the targeting of PPAR␥ to the 26 S proteasome. Interestingly, PPAR␥ levels in both IFN␥- and TZD-treated adipocytes
in the presence of proteasome inhibitors are less than the
control levels under the same conditions. This result is consistent with studies that demonstrate that both IFN␥ and TZDs
can also down-regulate PPAR␥ at the mRNA level (13, 37).
IFN␥-mediated Ubiquitin-PPAR␥ Conjugation—Ubiquitinproteasome-dependent degradation of a substrate requires two
separate steps. First, the substrate is targeted to the proteasome via covalent tagging of the substrate with a polyubiquitin
chain. The polyubiquitin-conjugated substrate is then recognized by the 26 S proteasome (22). These polyubiquitin-substrate conjugates are short lived, high molecular mass intermediates of the ubiquitin-proteasome pathway. Because IFN␥
affects PPAR␥ decay and this effect can be modulated by proteasome inhibitors, we hypothesized that there would be an
increase in polyubiquitin-PPAR␥ conjugates after IFN␥ treatment. To test this theory, we examined the formation of endogenous PPAR␥-ubiquitin adducts in 3T3-L1 adipocytes. PPAR␥
proteins were immunoprecipitated from whole cell extracts
that had been incubated in the presence or absence of IFN␥ for
the times indicated in Fig. 2. The immunoprecipitations were
analyzed by immunoblotting using either an anti-PPAR␥ anti-

FIG. 2. IFN␥ treatment is associated with an increase in
PPAR␥-ubiquitin conjugates in 3T3-L1 adipocytes. Fully differentiated 3T3-L1 adipocytes were treated with IFN␥ (100 units/ml) for
15 and 30 min after preincubation with MG132 (20 M) for 2 h. Control
samples were incubated for the same time period without the addition
of IFN␥. Whole cell extracts were harvested and immunoprecipitations
were performed as described under “Experimental Procedures” using
anti-PPAR␥. Western analysis was performed using either anti-PPAR␥
(left) or anti-ubiquitin (right). HC represents IgG heavy chain.

body (Fig. 2A) or an anti-ubiquitin (Fig. 2B) antibody. As shown
in Fig. 2, PPAR␥ was detected in high molecular mass forms
that are present under basal conditions and with increased
intensity after IFN␥ treatment. We also ectopically expressed
octameric HA-tagged ubiquitin and PPAR␥2 in NIH 3T3 cells
and observed ubiquitin conjugation of PPAR␥ under basal conditions and a significant increase in PPAR␥ ubiquitin conjugation following IFN␥ treatment (data not shown).
IFN␥-mediated Activation of PPAR␥—Based on our previous
studies showing that IFN␥ treatment of cultured adipocytes
has the dual effect of suppressing PPAR␥ transcription and
increasing PPAR␥ turnover (13), we hypothesized that IFN␥
treatment may also decrease the transcriptional activity of
PPAR␥. To test this prediction, we assayed the transcriptional
activity of PPAR␥ in NIH 3T3 cells using a luciferase reporter
(DR1 luciferase) construct containing three PPAR␥ response
elements. This construct has previously been used to measure
PPAR␥ activity (34, 38). In this experiment, we also examined
the effect of IFN␥ on the transcriptional activity of the phosphorylation-deficient PPAR␥2 S112A mutant. Numerous studies have shown that this mutant is more transcriptionally
active and that phosphorylation at this site is associated with
reduced PPAR␥ activity (39 – 41). To measure PPAR␥ activity,
NIH 3T3 cells were transiently cotransfected with DR1 luciferase and PPAR␥2 or PPAR␥2 S112A in pSVSport vectors in
the presence and absence of IFN␥ or TZD. As shown in Fig. 3,
IFN␥ treatment activates PPAR␥2 to the same extent as the
ligand-dependent activation associated with TZD treatment. In
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FIG. 3. IFN␥ mediates transcriptional activation of both wildtype PPAR␥ and PPAR␥ S112A. NIH 3T3 cells were cotransfected
with pDR1-luciferase and either wild-type PPAR␥ or PPAR␥ S112A.
The cells were also transfected with pSV-␤-galactosidase to correct for
variability in transfection efficiency. After 24 h, the cells were incubated with IFN␥ (100 units/ml) or darglitazone (TZD, 2.5 M) and
harvested 6 h later. PPAR␥ transcriptional activity was determined by
calculating the ratio of luciferase activity (relative light units, RLU) to
␤-galactosidase activity. The experiment was independently performed
in duplicate.

addition, activity of the PPAR␥2 S112A was greater than wildtype PPAR␥2, and the transcriptional activity of the mutant
was also significantly induced by IFN␥ treatment. However,
the mutant was more potently activated by TZD treatment.
The Role of Ser112 Phosphorylation in the Decay of PPAR␥—
Because IFN␥ and TZDs both activate PPAR␥ and target it for
degradation, we hypothesized that regulators of PPAR␥ activation could also contribute to PPAR␥ degradation. Therefore,
we examined the contribution of PPAR␥ Ser112 phosphorylation on PPAR␥ degradation because phosphorylation at this
site has profound effects on PPAR␥ activation. Fully differentiated 3T3-L1 adipocytes were pretreated with the MEK inhibitor, U0126, prior to the addition of IFN␥ or a vehicle control.
Turnover of PPAR␥ was then measured in the presence or
absence of cycloheximide. As shown in Fig. 4A, the turnover of
both PPAR␥1 and ␥2 was prolonged in the presence of the MEK
inhibitor (control ⫹ MEK I). We also observed that inhibition of
ERK1/2 activity abrogates the IFN␥-mediated decrease in the
half-life of PPAR␥ (Fig. 4A, IFN␥ ⫹ MEK I). The results in Fig.
4A clearly demonstrate that the presence of the MEK inhibitor
suppresses the decay of PPAR␥ proteins in adipocytes under
control and IFN␥-treated conditions. We also examined the
effect of IFN␥ and/or MEK I on PPAR␥ levels in the absence of
cycloheximide. The results in Fig. 4B confirm that ERKs 1 and
2 and play a role in degradation of PPAR␥ proteins under basal
as well as IFN␥-mediated conditions. In Fig. 4, A and B, the
expression of STAT 5A is shown as a loading control. The
results in Fig. 4A also indicate that the decay of PPAR␥ is much
quicker than the decay of PPAR␥2. Therefore, we performed an
additional decay experiment to compare the decay of ␥1 and ␥2.
Fully differentiated 3T3-L1 adipocytes were treated with cycloheximide, and whole cell extracts were isolated at various
times over a 6 h period. Fig. 5A shows the decay of PPAR␥
proteins under basal conditions. The ␥1 and ␥2 half-lives were
calculated to be 58 min and 1.45 h, respectively. The bottom
panel of Fig. 5A represents an enlarged display of four of the
time points from the top panel. As shown in this panel, we were

FIG. 4. Inhibition of ERK1/2 prolongs the half-life of PPAR␥
proteins in adipocytes. PPAR␥ expression was measured in the presence of 5 M cycloheximide (CH) (A) or under steady-state conditions (B)
under control or IFN␥ (100 units/ml)-treated conditions. Where indicated, the 3T3-L1 adipocytes were pretreated for 45 min with the MEK
inhibitor (MEK I), U0126 (5 M). B, the cells were harvested after a 2-h
incubation in the presence or absence of IFN␥. One hundred micrograms of each extract was separated by SDS-PAGE, transferred to
nitrocellulose, and subjected to Western blot analysis. Samples were
processed, and results were visualized as described in the Fig. 1 legend.
The molecular mass of each protein is indicated to the left of the blots
in kilodaltons. This was a representative experiment independently
performed three times.

also able to resolve the two bands of PPAR␥1, which represent
the Ser112-phosphorylated (upper band) and unphosphorylated
forms of the protein. The decay experiment in Fig. 5A clearly
demonstrates that PPAR␥1 is more labile than ␥2. In addition,
the unphosphorylated ␥1 disappears quicker than the phosphorylated form of ␥1. This pattern was also observed in the
presence of IFN␥. (Fig. 5B).
Cellular Location of PPAR␥ Degradation—The majority of
PPAR␥ proteins are found in the nucleus, and this raises the
possibility that the nuclear, rather than cytosolic, ubiquitinproteasome components may mediate the degradation of
PPAR␥. To address this question, we treated 3T3-L1 adipocytes
with IFN␥ alone or in the presence of either MG132 or leptomycin B (Fig. 6). LMB acts as an irreversible inhibitor of the
CRM-1-dependent nuclear export pathway via the modification
of Cys529 of CRM-1 (33) and has been used to determine
whether nuclear export is required for the degradation of nuclear proteins (42– 44). We examined the decay of PPAR␥ proteins following IFN␥ treatment in the presence of either
MG132 or LMB. The results in Fig. 6 indicate that MG132
prolongs the half-life of PPAR␥ proteins, and the presence of
LMB has no effect on PPAR␥ decay. To confirm LMB activity,
we assayed the cellular location of Mdm2 in 3T3-L1 adipocytes
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FIG. 5. PPAR␥1 is more labile than PPAR␥2, and the higher
mobility form of PPAR␥1 decays after the lower mobility form.
A, whole cell extracts were prepared from fully differentiated 3T3-L1
adipocytes after incubation in the presence of 5 M cycloheximide for
the indicated time points. Incubations were carried out in the absence
(A) or presence (B) of IFN␥ (100 units/ml). The lower panel (A) is an
enlargement of the indicated time points from the upper panel. One
hundred micrograms of each extract was separated by SDS-PAGE,
transferred to nitrocellulose, and subjected to Western blot analysis.
Samples were processed, and results were visualized as described in the
Fig. 1 legend. This was a representative experiment independently
performed three times.

in the absence or presence of LMB. Mdm2 has been characterized as an ubiquitin ligase (E3) that shuttles between the
nucleus and cytoplasm and is required for the degradation of
p53 (22). Although p53 expression is down-regulated during
differentiation of 3T3-L1 adipocytes, Mdm2 expression is maintained in fully differentiated 3T3-L1 adipocytes (45). Fig. 6B
demonstrates that Mdm2 accumulates in the nucleus in the
presence of LMB, indicating the effectiveness of LMB in these
experiments. These results demonstrate that CRM-1-dependent nuclear export is not required for the degradation of PPAR␥
following IFN␥ treatment and strongly suggests that PPAR␥ is
degraded in the nucleus.
DISCUSSION

The novel observations in this study include the increased
ubiquitin conjugation of PPAR␥ following IFN␥ treatment, the
activation of PPAR␥ transcriptional activity by IFN␥, evidence
that PPAR␥1 is substantially more labile than PPAR␥2, evidence that serine phosphorylation of PPAR␥ contributes to the
turnover of PPAR␥ proteins in adipocytes, and evidence that
PPAR␥ proteins are degraded by the nuclear ubiquitin-proteasome system. These results and recent findings by Spiegelman
and co-workers (34) indicate that ubiquitin-proteasome-mediated degradation of PPAR␥ is an important contributor to the
cellular levels of PPAR␥ proteins. Moreover, the cellular levels
of PPAR␥ appear to be important because transgenic mice that
express half the normal amount of PPAR␥ have been shown to
be more insulin sensitive (12).
In light of our current findings and the studies cited above
(13, 34, 39 – 41), we have formulated a model for the degradation of PPAR␥ proteins in adipocytes. This model, illustrated in

FIG. 6. PPAR␥ degradation in adipocytes does not depend on
nuclear export. A, fully differentiated 3T3-L1 adipocytes were incubated in the presence of cycloheximide (5 M) and harvested at the
indicated time points. The adipocytes were treated with IFN␥ alone or
in the presence of MG132 (20 M) or leptomycin B (10 nM) as indicated.
B, fully differentiated 3T3-L1 adipocytes were harvested after a 4-h
incubation in the presence of ethanol (⫺LMB) or leptomycin B (⫹LMB,
10 nM). Cytosolic and nuclear extracts were obtained as described under
“Experimental Procedures.” One hundred micrograms of each extract
were separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. Samples were processed, and results
were visualized as described in the Fig. 1 legend. This was a representative experiment independently performed two times.

Fig. 7, suggests that activation of PPAR␥ by IFN␥, TZDs, or
endogenous ligands is followed by ubiquitin-proteasome-mediated degradation. This model also suggests that serine phosphorylation contributes to PPAR␥ degradation. The validity of
this model is addressed in the following paragraphs.
Our results demonstrate that both PPAR␥1 and PPAR␥2 are
targeted to proteasome under basal conditions and following
IFN␥ treatment of adipocytes. We have also observed ubiquitin
conjugation of PPAR␥ under basal conditions and demonstrated a substantial increase in ubiquitin conjugation of
PPAR␥ after IFN␥ exposure. The increase in PPAR␥-ubiquitin
conjugates occurred within 15 min of IFN␥ treatment and
precedes the decrease in PPAR␥ observed in experiments
measuring PPAR␥ degradation. Our results demonstrating
that proteasome inhibitors reduce the effect of IFN␥ on PPAR␥
expression and the results demonstrating the appearance of
PPAR␥-polyubiquitin conjugates indicate that IFN␥ treatment
in adipocytes results in the rapid degradation of PPAR␥ via the
ubiquitin-proteasome pathway.
The rapid reduction in PPAR␥ mRNA and protein levels
following IFN␥ treatment (13) led us to predict that IFN␥
treatment would suppress PPAR␥ activity in adipocytes. Surprisingly, IFN␥ treatment of 3T3-L1 adipocytes was associated
with the transcriptional activation of PPAR␥2. Although unexpected, this result is consistent with the idea that nuclear
hormone receptor turnover occurs concomitantly with transcriptional activation of these transcription factors (24). Ligand-
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FIG. 7. Proposed model for degradation of PPAR␥. PPAR␥ activation is mediated by ligand binding or exposure to IFN␥. Phosphorylation of PPAR␥ influences the IFN␥ and ligand-dependent degradation
of PPAR␥.

dependent activation and subsequent degradation has been
demonstrated for several other nuclear hormone receptors (26 –
30), and the paradigm of activation followed by ubiquitin-proteasome-dependent degradation has been extended to proteins
such as protein kinase C (46). Although IFN␥ has not been
shown to be a ligand for PPAR␥, the activation of PPAR␥ is a
ligand-dependent process (47), and a recent study has demonstrated that PPAR␥2 degradation is associated with the TZDinduced activation of PPAR␥2 (34). Our data demonstrating
that IFN␥ treatment results in both the activation of PPAR␥2
and the ubiquitin-proteasome-mediated degradation of PPAR␥
suggest that IFN␥-mediated signaling in adipocytes may be associated with the binding of an endogenous ligand and the activation and subsequent degradation of PPAR␥. Moreover, IFN␥induced PPAR␥2 transcriptional activation is enhanced in the
phosphorylation-deficient S112A mutant of PPAR␥2. This result
is consistent with previous findings showing that the mutation of
Ser112 to alanine in PPAR␥ (Ser82 in PPAR␥1) is associated with
increased transcriptional activity (39, 40, 48).
The phosphorylation of PPAR␥ by MAPKs has been described in various studies (39 – 41, 48, 49). Although neither
IFN␥ nor TZDs directly activate ERKs 1 and 2 in adipocytes,
we found that inhibition of these MAPKs resulted in an inhibition of PPAR␥ decay. Therefore, the mechanism(s) by which
MAPKs influence PPAR␥ degradation is not clear. However,
phosphorylation plays an important role in targeting many
substrates for ubiquitination and can either inhibit or increase
the targeting of substrates to the ubiquitin-proteasome system
(22, 23). In our experiments, we observed that both PPAR␥1
and PPAR␥2 migrate as a doublet on gels that have been run
for 24 –30 h (refer to Fig. 5). This doublet is easily distinguishable for PPAR␥1. We confirmed that the slower migrating form
corresponds to serine-phosphorylated PPAR␥1, and the faster
migrating form represents the unphosphorylated PPAR␥1 proteins (data not shown), as has been previously described (34).
The results in Fig. 5 demonstrate that the faster migrating
form of PPAR␥1 disappears prior to the phosphorylated form of
the protein. The observed difference in the decay of these two
forms of PPAR␥1 suggest that phosphorylation of PPAR␥ proteins may serve as a ubiquitin-proteasome targeting signal in
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which PPAR␥ is converted to the phosphorylated form prior to
degradation by the ubiquitin-proteasome pathway. This hypothesis is also consistent with the increased activation the
S112A mutant, and we predict that the ubiquitin-conjugating
machinery may not recognize the phosphorylation-deficient
PPAR␥ as well as the wild-type protein. We hypothesize that
this may contribute to the increased activation observed with
the S112A mutant. This model is also supported by our data
demonstrating that inhibition of PPAR␥ serine phosphorylation with the MEK inhibitor prolongs the half-life of PPAR␥
proteins. All of these results support the hypothesis that serine
phosphorylation of PPAR␥ may influence its targeting to the
ubiquitin-proteasome system. However, recent work from the
Spiegelman laboratory (34) has shown that both the wild-type
and the S112A form of PPAR␥2 are degraded after ligand
activation, but they did not determine whether the half-lives of
these forms of the protein were different. Nonetheless, because
the phosphorylation-deficient mutant can be degraded, it
seems unlikely that serine phosphorylation is the only means
by which PPAR␥ proteins are targeted to the ubiquitin-proteasome system. Interestingly, the MAPK-regulated serine phosphorylation of the progesterone receptor has been shown act as
a targeting signal for the degradation of this protein (28, 50).
We also investigated the cellular location of the IFN␥-mediated ubiquitin-proteasome-dependent degradation of PPAR␥.
PPAR␥ proteins are predominantly localized in the nucleus,
and recent studies have demonstrated that the nuclear ubiquitin-proteasome is active in the degradation of selected substrates (42, 51, 52). Our results demonstrate that the IFN␥mediated degradation of PPAR␥ does not require CRM1dependent nuclear export, indicating that IFN␥-induced
PPAR␥ degradation likely occurs in the nucleus. In the absence
of serum deprivation, we observe active ERKs 1 and 2 in the
nucleus of 3T3-L1 adipocytes (data not shown) and hypothesize
that the presence of these kinases influences the nuclear decay
of PPAR␥ proteins. Finally, the observation that PPAR␥1 is
substantially more labile than PPAR␥2 suggests that recognition of PPAR␥ proteins by the ubiquitin-proteasome system in
adipocytes is influenced by the 30-amino acid N-terminal extension found in PPAR␥2. However, examination of the Nterminal residues of both forms of PPAR␥ reveals that neither
region contains the characteristic residues involved in the Nend rule targeting to the ubiquitin-proteasome system (53).
Moreover, neither form contains a lysine residue necessary for
ubiquitin conjugation (22). However, this study does not address the mechanisms underlying the differences in the halflives of PPAR␥1 and PPAR␥2.
Recent studies (12, 54) have shown that reduced PPAR␥
expression in mice (PPAR␥⫹/⫺) is associated with resistance to
weight gain along with protection from the insulin resistance
that typically accompanies weight gain. In addition, genetic
evidence indicates that decreased PPAR␥ activity may protect
against insulin resistance in humans (55). Conversely, PPAR␥
is required for the formation of fat cells, and a lack of adipose
cells is associated with insulin resistance and hyperglycemia
(56). These studies suggest that a careful balance between
PPAR␥ expression and activity levels must be maintained to
avoid development of diseases such as type II diabetes and
obesity. The current study, along with a previous study showing that ligand activation of PPAR␥ leads to ubiquitin-proteasome-dependent degradation of PPAR␥ (34), suggests that the
ubiquitin-proteasome pathway plays an important role in the
regulation of PPAR␥ expression in adipocytes.
REFERENCES
1. Egea, P. F., Klaholz, B. P., and Moras, D. (2000) FEBS Lett. 476, 62– 67
2. Zhu, Y., Qi, C., Korenberg, J. R., Chen, X. N., Noya, D., Rao, M. S., and Reddy,
J. K. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7921–7925

4068

IFN␥ Regulation of PPAR␥ Degradation

3. Fajas, L., Fruchart, J. C., and Auwerx, J. (1998) FEBS Lett. 438, 55– 60
4. Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., and Spiegelman, B. M.
(1994) Genes Dev. 8, 1224 –1234
5. Chawla, A., Schwarz, E. J., Dimaculangan, D. D., and Lazar, M. A. (1994)
Endocrinology 135, 798 – 800
6. Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., Ruiz-Lozano, P., Chien, K. R.,
Koder, A., and Evans, R. M. (1999) Mol. Cell 4, 585–595
7. Rosen, E. D., Sarraf, P., Troy, A. E., Bradwin, G., Moore, K., Milstone, D. S.,
Spiegelman, B. M., and Mortensen, R. M. (1999) Mol. Cell 4, 611– 617
8. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson,
T. M., and Kliewer, S. A. (1995) J. Biol. Chem. 270, 12953–12956
9. Willson, T. M., Cobb, J. E., Cowan, D. J., Wiethe, R. W., Correa, I. D., Prakash,
S. R., Beck, K. D., Moore, L. B., Kliewer, S. A., and Lehmann, J. M. (1996)
J. Med. Chem. 39, 665– 668
10. Barroso, I., Gurnell, M., Crowley, V. E., Agostini, M., Schwabe, J. W., Soos,
M. A., Maslen, G. L., Williams, T. D., Lewis, H., Schafer, A. J., Chatterjee,
V. K., and O’Rahilly, S. (1999) Nature 402, 880 – 883
11. Rieusset, J., Andreelli, F., Auboeuf, D., Roques, M., Vallier, P., Riou, J. P.,
Auwerx, J., Laville, M., and Vidal, H. (1999) Diabetes 48, 699 –705
12. Miles, P. D., Barak, Y., He, W., Evans, R. M., and Olefsky, J. M. (2000) J. Clin.
Invest. 105, 287–292
13. Waite, K. J., Floyd, Z. E., Arbour-Reily, P., and Stephens, J. M. (2001) J. Biol.
Chem. 276, 7062–7068
14. Doerrler, W., Feingold, K. R., and Grunfeld, C. (1994) Cytokine 6, 478 – 484
15. Gregoire, F., De Broux, N., Hauser, N., Heremans, H., Van Damme, J., and
Remacle, C. (1992) J. Cell. Physiol. 151, 300 –309
16. Keay, S., and Grossberg, S. E. (1980) Proc. Natl. Acad. Sci. U. S. A. 77,
4099 – 4103
17. Grossberg, S. E., and Keay, S. (1980) Ann. N. Y. Acad. Sci. 350, 294 –300
18. Stephens, J. M., Lumpkin, S. J., and Fishman, J. B. (1998) J. Biol. Chem. 273,
31408 –31416
19. Khanna, S., Roy, S., Packer, L., and Sen, C. K. (1999) Am. J. Physiol. 276,
R1327-R1333
20. Koivisto, V. A., Pelkonen, R., and Cantell, K. (1989) Diabetes 38, 641– 647
21. Shiba, T., Higashi, N., and Nishimura, Y. (1998) Diabetes Med. 15, 435– 436
22. Hershko, A., and Ciechanover, A. (1998) Annu. Rev. Biochem. 67, 425– 479
23. Weissman, A. M. (2001) Nat. Rev. Mol. Cell. Biol. 2, 169 –178
24. Dennis, A. P., Haq, R. U., and Nawaz, Z. (2001) Front. Biosci. 6, D954-D959
25. McKenna, N. J., Xu, J., Nawaz, Z., Tsai, S. Y., Tsai, M. J., and O’Malley, B. W.
(1999) J. Steroid Biochem. Mol. Biol. 69, 3–12
26. Lonard, D. M., Nawaz, Z., Smith, C. L., and O’Malley, B. W. (2000) Mol. Cell
5, 939 –948
27. Nawaz, Z., Lonard, D. M., Dennis, A. P., Smith, C. L., and O’Malley, B. W.
(1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1858 –1862
28. Lange, C. A., Shen, T., and Horwitz, K. B. (2000) Proc. Natl. Acad. Sci. U. S. A.
97, 1032–1037
29. Dace, A., Zhao, L., Park, K. S., Furuno, T., Takamura, N., Nakanishi, M., West,
B. L., Hanover, J. A., and Cheng, S. (2000) Proc. Natl. Acad. Sci. U. S. A. 97,
8985– 8990

30. Roberts, B. J., and Whitelaw, M. L. (1999) J. Biol. Chem. 274, 36351–36356
31. Hershko, A., Ciechanover, A., and Varshavsky, A. (2000) Nat. Med. 6,
1073–1081
32. Laemmli, U. K. (1970) Nature 227, 680 – 685
33. Kudo, N., Matsumori, N., Taoka, H., Fujiwara, D., Schreiner, E. P., Wolff, B.,
Yoshida, and Horinouchi, S. (1999) Proc. Natl. Acad. Sci. U. S. A. 96,
9112–9117
34. Hauser, S., Adelmant, G., Sarraf, P., Wright, H. M., Mueller, E., and
Spiegelman, B. M. (2000) J. Biol. Chem. 275, 18527–18533
35. Lee, D. H., and Goldberg, A. L. (1998) Trends Cell Biol. 8, 397– 403
36. Meng, L., Mohan, R., Kwok, B. H., Elofsson, M., Sin, N., and Crews, C. M.
(1999) Proc. Natl. Acad. Sci. U. S. A. 96, 10403–10408
37. Rosenbaum, S. E., and Greenberg, A. S. (1998) Mol. Endocrinol. 12, 1150 –1160
38. Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., and
Evans, R. M. (1995) Cell 83, 803– 812
39. Hu, E., Kim, J. B., Sarraf, P., and Spiegelman, B. M. (1996) Science 274,
2100 –2103
40. Camp, H. S., and Tafuri, S. R. (1997) J. Biol. Chem. 272, 10811–10816
41. Camp, H. S., Tafuri, S. R., and Leff, T. (1999) Endocrinology 140, 392–397
42. Floyd, Z. E., Trausch-Azar, J. S., Reinstein, E., Ciechanover, A., and Schwartz,
A. L. (2001) J. Biol. Chem. 276, 22468 –22475
43. Alt, J. R., Cleveland, J. L., Hannink, M., and Diehl, J. A. (2000) Genes Dev. 14,
3102–3114
44. Henderson, B. R. (2000) Nat. Cell. Biol. 2, 653– 660
45. Berberich, S. J., Vaughn, L., Mayo, L. D., Tabesh, D., and Morris, D. (1999)
Differentiation 64, 205–212
46. Lu, Z., Liu, D., Hornia, A., Devonish, W., Pagano, M., and Foster, D. A. (1998)
Mol. Cell. Biol. 18, 839 – 845
47. Rosen, E. D., Walkey, C. J., Puigserver, P., and Spiegelman, B. M. (2000) Genes
Dev. 14, 1293–1307
48. Adams, M., Reginato, M. J., Shao, D., Lazar, M. A., and Chatterjee, V. K.
(1997) J. Biol. Chem. 272, 5128 –5132
49. Zhang, B., Berger, J., Zhou, G., Elbrecht, A., Biswas, S., White-Carrington, S.,
Szalkowski, D., and Moller, D. E. (1996) J. Biol. Chem. 271, 31771–31774
50. Shen, T., Horwitz, K. B., and Lange, C. A. (2001) Mol. Cell. Biol. 21, 6122– 6131
51. Blondel, M., Galan, J. M., Chi, Y., Lafourcade, C., Longaretti, C., Deshaies,
R. J., and Peter, M. (2000) EMBO J. 19, 6085– 6097
52. Lenk, U., and Sommer, T. (2000) J. Biol. Chem. 275, 39403–39410
53. Varshavsky, A., Turner, G., Du, F., and Xie, Y. (2000) Biol. Chem. HoppeSeyler 381, 779 –789
54. Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K.,
Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., Eto, K., Tsubamoto, Y.,
Okuno, A., Murakami, K., Sekihara, H., Hasegawa, G., Naito, M.,
Toyoshima, Y., Tanaka, S., Shiota, K., Kitamura, T., Fujita, T., Ezaki, O.,
Aizawa, S., and Kadowaki, T. (1999) Mol. Cell 4, 597– 609
55. Deeb, S. S., Fajas, L., Nemoto, M., Pihlajamaki, J., Mykkanen, L., Kuusisto, J.,
Laakso, M., Fujimoto, W., and Auwerx, J. (1998) Nat. Genet. 20, 284 –287
56. Willson, T. M., Lambert, M. H., and Kliewer, S. A. (2001) Annu. Rev. Biochem.
70, 341–367

